The role of CDK4/6 inhibitors in early breast cancer

by Gil-Gil, Miguel, Alba, Emilio, Gavilá, Joaquín, de la Haba-Rodríguez, Juan, Ciruelos, Eva, Tolosa, Pablo, Candini, Daniele, Llombart-Cussac, Antonio
Published in Breast (2021)

Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy

by Herrero-Vicent, Carmen, Guerrero, Angel, Gavilá, Joaquin, Gozalbo, Francisco, Hernández, Abraham, Sandiego, Sergio, Algarra, Maria Asunción, Calatrava, Ana, Guillem-Porta, Vicente, Ruiz-Simón, Amparo
Published in Ecancermedicalscience (2017)

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

by Garcia-Casado, Zaida, Guerrero-Zotano, Angel, Llombart-Cussac, Antonio, Calatrava, Ana, Fernandez-Serra, Antonio, Ruiz-Simon, Amparo, Gavila, Joaquin, Climent, Miguel A, Almenar, Sergio, Cervera-Deval, Jose, Campos, Josefina, Albaladejo, Carlos Vazquez, Llombart-Bosch, Antonio, Guillem, Vicente, Lopez-Guerrero, Jose A
Published 2010

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

by Pajares, Bella, Pollán, Marina, Martín, Miguel, Mackey, John R, Lluch, Ana, Gavila, Joaquín, Vogel, Charles, Ruiz-Borrego, Manuel, Calvo, Lourdes, Pienkowski, Tadeusz, Rodríguez-Lescure, Álvaro, Seguí, Miguel Angel, Tredan, Olivier, Antón, Antonio, Ramos, Manuel, Cámara, María del Carmen, Rodríguez-Martín, César, Carrasco, Eva, Alba, Emilio
Published 2013

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opt...

by Gavilá, Joaquín, Oliveira, Mafalda, Pascual, Tomás, Perez-Garcia, Jose, Gonzàlez, Xavier, Canes, Jordi, Paré, Laia, Calvo, Isabel, Ciruelos, Eva, Muñoz, Montserrat, Virizuela, Juan A., Ruiz, Isabel, Andrés, Raquel, Perelló, Antonia, Martínez, Jerónimo, Morales, Serafín, Marín-Aguilera, Mercedes, Martínez, Débora, Quero, Juan C., Llombart-Cussac, Antonio, Prat, Aleix
Published in BMC Med (2019)

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cance...

by Llombart-Cussac, Antonio, Bermejo, Begoña, Villanueva, Cristian, Delaloge, Suzette, Morales, Serafín, Balmaña, Judith, Amillano, Kepa, Bonnefoi, Hervé, Casas, Ana, Manso, Luis, Roché, Henri, Gonzalez-Santiago, Santiago, Gavilá, Joaquín, Sánchez-Rovira, Pedro, Di Cosimo, Serena, Harbeck, Nadia, Charpentier, Eric, Garcia-Ribas, Ignacio, Radosevic-Robin, Nina, Aura, Claudia, Baselga, Jose
Published in Breast Cancer Res Treat (2015)

Independent validation of the PAM50-based Chemo-Endocrine Score (CES) in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy

by Pascual, Tomás, Fernandez-Martinez, Aranzazu, Tanioka, Maki, Dieci, M. Vittoria, Pernas, Sonia, Gavila, Joaquin, Guarnieri, Valentina, Cortes, Javier, Villagrasa, Patricia, Chic, Núria, Vidal, Maria, Adamo, Barbara, Muñoz, Montserrat, Griguolo, Gaia, Llombart, Antonio, Conte, Pierfranco, Oliveira, Mafalda, Conte, Benedetta, Paré, Laia, Galvan, Patricia, Carey, Lisa A., Perou, Charles M., Prat, Aleix
Published in Clin Cancer Res (2021)

Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy

by Chic, Nuria, Schettini, Francesco, Brasó-Maristany, Fara, Sanfeliu, Esther, Adamo, Barbara, Vidal, Maria, Martínez, Débora, Galván, Patricia, González-Farré, Blanca, Cortés, Javier, Gavilá, Joaquín, Saura, Cristina, Oliveira, Mafalda, Pernas, Sònia, Martínez-Sáez, Olga, Soberino, Jesús, Ciruelos, Eva, Carey, Lisa A., Muñoz, Montserrat, Perou, Charles M., Pascual, Tomás, Bellet, Meritxell, Prat, Aleix
Published in EBioMedicine (2021)

ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors

by Guerrero-Zotano, Angel L., Stricker, Thomas P., Formisano, Luigi, Hutchinson, Katherine E., Stover, Daniel G., Lee, Kyung-min, Schwarz, Luis J., Giltnane, Jennifer M., Estrada, Valeria M., Jansen, Valerie M., Servetto, Alberto, Gavilá, Joaquín, Perez-Fidalgo, J. Alejandro, Lluch, Ana, Llombart, Antonio, Bayar, Mohamed A., Michiels, Stefan, André, Fabrice, Arnedos, Mónica, Guillem, Vicente, Ruiz, Amparo, Arteaga, Carlos L.
Published in Clin Cancer Res (2018)

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

by Garrido-Castro, Ana C., Saura, Cristina, Barroso-Sousa, Romualdo, Guo, Hao, Ciruelos, Eva, Bermejo, Begoña, Gavilá, Joaquin, Serra, Violeta, Prat, Aleix, Paré, Laia, Céliz, Pamela, Villagrasa, Patricia, Li, Yisheng, Savoie, Jennifer, Xu, Zhan, Arteaga, Carlos L., Krop, Ian E., Solit, David B., Mills, Gordon B., Cantley, Lewis C., Winer, Eric P., Lin, Nancy U., Rodon, Jordi
Published in Breast Cancer Res (2020)

Correction: ER(+) Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

by Guerrero-Zotano, Angel L., Stricker, Thomas P., Formisano, Luigi, Hutchinson, Katherine E., Stover, Daniel G., Lee, Kyung-Min, Schwarz, Luis J., Giltnane, Jennifer M., Estrada, Monica V., Jansen, Valerie M., Servetto, Alberto, Gavilá, Joaquín, Perez-Fidalgo, J. Alejandro, Lluch, Ana, Llombart-Cussac, Antonio, Bayar, Mohamed Amine, Michiels, Stefan, André, Fabrice, Arnedos, Mόnica, Guillem, Vicente, Ruiz-Simon, Amparo, Arteaga, Carlos L.
Published in Clin Cancer Res (2019)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

by Schettini, Francesco, Chic, Nuria, Brasó-Maristany, Fara, Paré, Laia, Pascual, Tomás, Conte, Benedetta, Martínez-Sáez, Olga, Adamo, Barbara, Vidal, Maria, Barnadas, Esther, Fernández-Martinez, Aranzazu, González-Farre, Blanca, Sanfeliu, Esther, Cejalvo, Juan Miguel, Perrone, Giuseppe, Sabarese, Giovanna, Zalfa, Francesca, Peg, Vicente, Fasani, Roberta, Villagrasa, Patricia, Gavilá, Joaquín, Barrios, Carlos H., Lluch, Ana, Martín, Miguel, Locci, Mariavittoria, De Placido, Sabino, Prat, Aleix
Published in NPJ Breast Cancer (2021)

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

by Bellet, Meritxell, Ahmad, Faten, Villanueva, Rafael, Valdivia, Carolina, Palomino-Doza, Julián, Ruiz, Ada, Gonzàlez, Xavier, Adrover, Encarna, Azaro, Analía, Valls-Margarit, Maria, Parra, Josep Lluís, Aguilar, Juan, Vidal, Maria, Martín, Anastasi, Gavilá, Joaquín, Escrivá-de-Romaní, Santiago, Perelló, Antonia, Hernando, Cristina, Lahuerta, Ainhara, Zamora, Pilar, Reyes, Victoria, Alcalde, María, Masanas, Helena, Céliz, Pamela, Ruíz, Isabel, Gil, Miguel, Seguí, Miguel Àngel, de la Peña, Lorena
Published in Ther Adv Med Oncol (2019)

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

by Pascual, Tomás, Oliveira, Mafalda, Ciruelos, Eva, Bellet Ezquerra, Meritxell, Saura, Cristina, Gavilá, Joaquin, Pernas, Sonia, Muñoz, Montserrat, Vidal, Maria J., Margelí Vila, Mireia, Cejalvo, Juan M., González-Farré, Blanca, Espinosa-Bravo, Martin, Cruz, Josefina, Salvador-Bofill, Francisco Javier, Guerra, Juan Antonio, Luna Barrera, Ana María, Arumi de Dios, Miriam, Esker, Stephen, Fan, Pang-Dian, Martínez-Sáez, Olga, Villacampa, Guillermo, Paré, Laia, Ferrero-Cafiero, Juan M., Villagrasa, Patricia, Prat, Aleix
Published in Front Oncol (2021)